Axogen Inc (AXGN)

Currency in USD
12.55
-0.12(-0.95%)
Closed·
Pre Market
14.80+2.25(+17.93%)
·
AXGN Scorecard
Full Analysis
Net income is expected to grow this year
Unusual Pre-Market activity
Fair Value
Day's Range
12.3912.93
52 wk Range
7.7121.00
Key Statistics
Prev. Close
12.55
Open
12.68
Day's Range
12.39-12.93
52 wk Range
7.71-21
Volume
1.55M
Average Volume (3m)
957.43K
1-Year Change
54.94%
Book Value / Share
2.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AXGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.29
Upside
+93.51%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

Axogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Axogen Inc Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Axogen Inc SWOT Analysis


Nerve Repair Pionee
Explore AxoGen's innovative solutions in peripheral nerve injury, driving its market leadership and expanding its addressable market to $5.6 billion
Financial Trajectory
Delve into AxoGen's robust revenue growth and long-term projections, including a 15-20% CAGR and anticipated profitability by 2025
Regulatory Catalyst
Learn about the potential game-changing BLA approval for Avance Nerve Graft, expected in September 2025, which could grant 12+ years of market exclusivity
Analyst Optimism
Discover why analysts set price targets ranging from $24 to $26, reflecting confidence in AxoGen's strategic initiatives and market expansion
Read full SWOT analysis

Axogen Inc Earnings Call Summary for Q1/2025

  • AxoGen reported Q1 2025 adjusted net loss of $0.02/share, missing $0.02 EPS forecast; revenue grew 17.4% YoY to $48.6M, slightly below expectations
  • Stock tumbled 14.28% premarket on earnings miss; company maintains 15-17% full-year revenue growth guidance and 73-75% gross margin target
  • Expanding sales force and targeting high-potential accounts; expects BLA approval for AVANCE nerve graft in September
  • CEO emphasizes focus on high-potential providers and positioning to address nerve injury challenges; aims to be cash flow positive
  • Analysts maintain strong buy consensus with price targets $24-$30; InvestingPro data suggests current valuation is fairly valued
Last Updated: 08/05/2025, 14:22
Read Full Transcript

Compare AXGN to Peers and Sector

Metrics to compare
AXGN
Peers
Sector
Relationship
P/E Ratio
−79.8x−3.5x−0.5x
PEG Ratio
−1.18−0.190.00
Price/Book
5.4x2.8x2.6x
Price / LTM Sales
2.9x2.4x3.3x
Upside (Analyst Target)
91.2%66.3%43.5%
Fair Value Upside
Unlock3.4%6.3%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.29
(+93.51% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.12 / 0.06
Revenue / Forecast
56.66M / 52.66M
EPS Revisions
Last 90 days

AXGN Income Statement

People Also Watch

47.82
STNG
+1.64%
17.180
QBTS
+4.88%
5.71
REPL
-24.87%
12.99
SLP
+1.48%
23.91
JANX
+1.49%

FAQ

What Stock Exchange Does Axogen Inc Trade On?

Axogen Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Axogen Inc?

The stock symbol for Axogen Inc is "AXGN."

What Is the Axogen Inc Market Cap?

As of today, Axogen Inc market cap is 571.58M.

What Is Axogen Inc's Earnings Per Share (TTM)?

The Axogen Inc EPS (TTM) is -0.16.

When Is the Next Axogen Inc Earnings Date?

Axogen Inc will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is AXGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Axogen Inc Stock Split?

Axogen Inc has split 0 times.

How Many Employees Does Axogen Inc Have?

Axogen Inc has 452 employees.

What is the current trading status of Axogen Inc (AXGN)?

As of 05 Aug 2025, Axogen Inc (AXGN) is trading at a price of 12.55, with a previous close of 12.55. The stock has fluctuated within a day range of 12.39 to 12.93, while its 52-week range spans from 7.71 to 21.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.